---
layout: default
title: Desogestrel
parent: 僅模型預測 (L5)
nav_order: 109
evidence_level: L5
indication_count: 10
---

# Desogestrel
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Desogestrel: Evaluation Incomplete — No Predicted Indications Available

## One-Sentence Summary

Desogestrel (DB00304) is a synthetic progestogen used in oral contraceptives and hormone-based therapies. The current Evidence Pack contains **no TxGNN predicted indications** for this drug, and critical data including original indications, mechanism of action, and safety information are unavailable. A complete repurposing evaluation cannot be conducted until these data gaps are resolved.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available in this Evidence Pack |
| Predicted New Indication | None — TxGNN returned no predictions |
| TxGNN Prediction Score | N/A |
| Evidence Level | N/A (no prediction to evaluate) |
| New Zealand Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | **Hold** |

---

## Why This Evaluation Cannot Proceed

The Evidence Pack for Desogestrel is missing two categories of foundational data required for a repurposing assessment:

**No TxGNN Predictions.** The `predicted_indications` array is empty. This may indicate that Desogestrel was not successfully embedded in the knowledge graph, that its node lacked sufficient connections to generate high-confidence predictions, or that the prediction pipeline encountered an upstream error. Without a target indication, no clinical or mechanistic analysis can follow.

**No Mechanism of Action (MOA) Data.** Although a DrugBank query returned one result (query log entry #3), the MOA field was not populated in the Evidence Pack. Desogestrel is a third-generation synthetic progestogen that binds progesterone receptors and suppresses ovulation; however, citing this from general knowledge rather than the structured data source would not meet the evidence standards required for a repurposing report.

**No Original Indications Recorded.** The `original_indications` array is empty, making it impossible to characterise the drug's approved therapeutic context or establish a mechanistic bridge to any new indication.

---

## New Zealand Market Information

Desogestrel has **no registered authorisations** in the New Zealand database as of the data cutoff (2026-04-20).

| Item | Status |
|------|--------|
| Market status | Not marketed |
| Total authorisations | 0 |
| Available dosage forms | None on record |

---

## Safety Considerations

Please refer to the package insert for safety information.

> No safety data (warnings, contraindications, or drug interactions) was returned in this Evidence Pack. A TFDA package insert query was logged as successful (query log entry #4), but the structured output was not populated. DDI query returned no results (query log entry #2).

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The absence of TxGNN predictions means there is no repurposing candidate to evaluate. All downstream sections — clinical trial evidence, literature review, mechanism analysis, and cytotoxicity assessment — depend on a predicted indication existing. Proceeding without one would produce a report with no clinical substance.

**To proceed, the following is needed:**

1. **Re-run TxGNN prediction pipeline** for DB00304 and confirm whether the drug node exists in the knowledge graph and has qualifying edges.
2. **Populate MOA from DrugBank API** — the query returned a record (result_count: 1) but the field was not extracted; re-parse the DrugBank response to retrieve mechanism, pharmacology, and drug categories.
3. **Extract TFDA package insert content** — the insert query was logged as successful but no warnings or contraindications were populated; re-parse the PDF to extract structured safety data (DG001, Blocking severity).
4. **Confirm original indications** — retrieve approved indication text from either the DrugBank record or regulatory sources so the drug's therapeutic baseline can be established.
5. Once the above are resolved, re-generate the Evidence Pack (target: v5) and resubmit for full evaluation.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

